Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion

NCT01179191 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01179191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01179191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2010
Completion date
April 30, 2011
Enrollment
684 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

chronic disease, pain